Autres langues N4 Pharma Plc

Actions

Marché Fermé - London S.E. Autres places de cotation 17:35:05 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,775 ^GBX	-6,06 %		-8,82 %	-8,82 %

25/04	N4 Pharma conclut un accord de partenariat pour l'administration intracellulaire	AN
23/04	La perte de N4 Pharma se creuse mais l'optimisme reste de mise	AN

N4 Pharma strikes partnership deal for intracellular delivery	25/04
N4 Pharma loss widens but "great optimism" remains	23/04
N4 Pharma Plc Reports Earnings Results for the Full Year Ended December 31, 2023	23/04
N4 Pharma sees potential in Nuvec delivery method for cancer treatment	18/04
N4 Pharma’s In Vivo Testing Shows Nuvec’s Potential as Oral Delivery System	18/04
Police Arrest Two Over Attempt to Kill Murder Case	16/04
N4 Pharma's In-vitro Study Shows Nuvec's Versatility in Inhibiting Cancer Cells	15/02
N4 Pharma shares rise on "encouraging" Nuvec research	15/02
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	15/02
N4 Pharma plc Provides In-Vitro siRNA Update	15/02
N4 Pharma's Nuvec Granted Patent in India	19/01
N4 Pharma gets India patent for medical delivery system	19/01
N4 Pharma touts contract to test glaucoma treatment, ECP105	16/01
N4 Pharma Unit to Prepare Glaucoma Treatment Candidate for Pre-clinical Trials; Shares Plunge	16/01
N4 Pharma Shows Increased Transduction Efficacy for Silica Nanoparticle	08/01
N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8	08/01
N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral Vector	08/01
FTSE 100 outperforms European peers	18/12
N4 Pharma rises on successful results from Nuvec administration	18/12
N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research Work	18/12

Aucun résultat pour cette recherche